Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms
- PMID: 40001347
- DOI: 10.1002/path.6402
Tumor immune microenvironment alterations associated with progression in human intraductal papillary mucinous neoplasms
Abstract
Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to late-stage diagnoses. To improve patient outcomes, early intervention in precursor lesions such as intraductal papillary mucinous neoplasm (IPMN) is crucial. However, early intervention must be balanced against overtreatment of low-risk lesions that are unlikely to progress, underscoring the need to better understand molecular alterations in neoplastic cells and changes in the tumor microenvironment (TME) that drive the progression of IPMNs. In this study, we characterized alterations in the TME of IPMNs as they progressed to high-grade dysplasia, using immunohistochemistry to quantify immune cell density and activation status in more than 100 well-characterized human IPMN samples. Analyses revealed progression to a more immunosuppressive TME in high-grade IPMN compared with low-grade IPMN, characterized by elevated expression of immune checkpoint molecules (PD-L1, TIM3, VISTA), increased density of macrophages, and decreased density of cytotoxic T cells. Intriguingly, the alterations in macrophages were limited to focal regions of high-grade dysplasia, while T-cell alterations affected the entire IPMN. Additionally, elevated VISTA expression was associated with poorer clinical outcome after IPMN resection in an independent cohort. These findings provide important insights into the interplay between the immune microenvironment and IPMN progression, highlighting potential targets to modify the TME for cancer interception. © 2025 The Pathological Society of Great Britain and Ireland.
Keywords: cancer immunology; immune checkpoint; immune evasion; immunosuppressive microenvironment; intraductal papillary mucinous neoplasm; lymphocyte infiltration; pancreatic ductal adenocarcinoma; tumor heterogeneity; tumor immune microenvironment; tumor progression.
© 2025 The Pathological Society of Great Britain and Ireland.
References
-
- Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721–733.
-
- Okano K, Suzuki Y. Strategies for early detection of resectable pancreatic cancer. World J Gastroenterol 2014; 20: 11230–11240.
-
- Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbeck's Arch Surg 1998; 383: 129–133.
-
- Singhi AD, Wood LD. Early detection of pancreatic cancer using DNA‐based molecular approaches. Nat Rev Gastroenterol Hepatol 2021; 18: 457–468.
-
- Pereira SP, Oldfield L, Ney A, et al. Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol 2020; 5: 698–710.
Publication types
MeSH terms
Substances
Grants and funding
- IPMN Global Foundation
- AACR-Bristol-Myers Squibb Midcareer Female Investigator
- Joseph C. Monastra Foundation for Pancreatic Cancer Research
- Rolfe Pancreatic Cancer Foundation
- Dennis Troper and Susan Wojcicki
- The Gerald O Mann Charitable Foundation
- K08 DK107781/DK/NIDDK NIH HHS/United States
- P50 CA62924/CA/NCI NIH HHS/United States
- Buffone Family Gastrointestinal Cancer Research Fund
- Sol Goldman Pancreatic Cancer Research Center
- K08 DK107781/DK/NIDDK NIH HHS/United States
- P50 CA62924/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
